Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”

We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses.

A caller asked what Cramer’s thoughts on Eli Lilly and Company (NYSE:LLY) were, and he commented:

“Okay, Eli Lilly. We bought some just the other day for the Charitable Trust. Why did we do that? Because it’s down very big and yet it’s been beating Novo Nordisk over and over and over again. So I just think this is a decent level to start a position if you don’t have any.”

Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”

Eli Lilly (NYSE:LLY) focuses on researching, developing, and bringing to market a wide range of medicines, including treatments for diabetes, cancer, autoimmune conditions, pain, and migraines. When Cramer was asked about the company around 2 weeks ago, he stated:

“I want you to buy more… The reason why you want to buy it is because there was definitive data that came out last night about Novo Nordisk not being anywhere near as good as Eli Lilly when it comes to weight loss, which is what a lot of people are in the GLP for. And it was not reflected because the things were so crazed because of what the president announced. I think the stock could be up a hundred points when people realize, wait a second, it is definitively better than Novo. I would buy Eli Lilly handover fist.”

Overall, LLY ranks 4th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.